Advertisement

Emerging Roles of Sympathetic Nerves and Inflammation in Perivascular Adipose Tissue

  • Sophie N. SaxtonEmail author
  • Sarah B. Withers
  • Anthony M. Heagerty
Open Access
ORIGINAL ARTICLE

Abstract

Perivascular adipose tissue (PVAT) is no longer recognised as simply a structural support for the vasculature, and we now know that PVAT releases vasoactive factors which modulate vascular function. Since the discovery of this function in 1991, PVAT research is rapidly growing and the importance of PVAT function in disease is becoming increasingly clear. Obesity is associated with a plethora of vascular conditions; therefore, the study of adipocytes and their effects on the vasculature is vital. PVAT contains an adrenergic system including nerves, adrenoceptors and transporters. In obesity, the autonomic nervous system is dysfunctional; therefore, sympathetic innervation of PVAT may be the key mechanistic link between increased adiposity and vascular disease. In addition, not all obese people develop vascular disease, but a common feature amongst those that do appears to be the inflammatory cell population in PVAT. This review will discuss what is known about sympathetic innervation of PVAT, and the links between nerve activation and inflammation in obesity. In addition, we will examine the therapeutic potential of exercise in sympathetic stimulation of adipose tissue.

Keywords

Adipose tissue Inflammation Obesity Sympathetic nerves Exercise 

Abbreviations

BAT

Brown adipose tissue

FFAs

Free fatty acids

IL-6

Interleukin-6

NA

Noradrenaline

OCT3

Organic cation transporter 3

PVAT

Perivascular adipose tissue

SNS

Sympathetic nervous system

TNF-α

Tumour necrosis factor α

WAT

White adipose tissue

Introduction

Obesity is increasingly prevalent and is currently estimated to affect around 30% of adults in the UK [1]. Obesity is associated with a cluster of health conditions known as the metabolic syndrome, including hypertension and type-II diabetes, all of which may contribute to reduced life expectancy [2, 3]. It is estimated that obesity costs the UK’s National Health Service £4.2 billion per year [4], which presents a considerable burden to society. Therefore, there is a need to transform obese patients into metabolically fit individuals. One might assume that the simple solution is weight loss; however, clinical studies have indicated that most patients will regain weight lost through diet [5]. This highlights a need for new therapeutic strategies in place of caloric restriction.

We live in an age of convenience; high-calorie foods are readily available, with less need to expend energy. As a result of excess energy intake, adipose tissue depots expand. However, adipose tissue is not just an energy store and is actually a highly metabolically active endocrine organ [6, 7, 8, 9]. Perivascular adipose tissue (PVAT) surrounds a number of peripheral vascular beds and is comprised of dynamic cell populations in addition to adipocytes, which includes nerves, stem cells, microvasculature and a plethora of immune cells [6, 10, 11]. There is a wealth of evidence that PVAT secretes vasoactive factors, which modulate vascular tone in isolated arteries [12, 13, 14]. Many of these factors are reported to have anti-contractile effects on resistance arteries, skeletal muscle arteries and the aorta, reducing peripheral resistance [11, 15, 16, 17]. Therefore, these factors are likely to contribute to modulating blood pressure in vivo [14]. In obesity, where autonomic dysfunction is known to occur, PVAT becomes inflamed and its secretory profile becomes dysfunctional [11, 18]. Loss of PVAT function may contribute to the vascular complications associated with obesity such as hypertension and type-II diabetes [19, 20, 21, 22].

In this review, we will discuss the roles of sympathetic innervation in adipose tissue phenotype and function, and highlight the consequences of autonomic dysfunction within PVAT. In addition, we will cover the inflammatory environment in obese PVAT, and explore the links between sympathetic innervation and inflammation.

Adipocytes: More than Fat Stores

There are two classical and functionally different types of adipocytes: white and brown. White adipose tissue (WAT) is widespread in the body, comprising the majority of visceral, subcutaneous and perivascular adipose depots, and one function is to provide support and insulation for the organs and vessels it surrounds [23]. White adipocytes are most widely recognised as a form of energy storage, and they contain a large lipid droplet for storing free fatty acids [24]. Therefore, it is white adipocytes which proliferate and expand in obesity. However, the belief that WAT is purely an energy store has long since passed, and we now know that adipocytes secrete almost 100 different proteins including vasoactive adipokines and inflammatory cytokines which play a number of roles including modulation of vascular tone, insulin resistance and body weight regulation [23, 25, 26, 27]. In addition to this diverse secretory profile, adipocytes express receptors for a number of substrates including neurotransmitters, indicating a role for the nervous system in regulating adipocyte function.

Whilst white adipocytes store energy, brown adipocytes expend it, and are well known for their role in thermogenesis, particularly in infants. These smaller adipocytes, with a large number of mitochondria, produce heat through uncoupled respiration [23, 28, 29]. Brown adipose tissue (BAT) depots are highly vascularised compared to WAT, which allows for efficient dispersal of heat. Since brown adipocytes are associated with energy expenditure, it has been proposed that brown adipocytes may confer metabolic improvements in obesity, where there is an imbalance between energy intake and expenditure [30, 31]. Indeed in mouse models, BAT transplants have demonstrated the potential usefulness of brown adipocytes. When BAT was transplanted into the visceral cavity of obese mice, insulin resistance was completely reversed and whole body metabolism increased, which reduced total body fat mass [32, 33]. However, whilst BAT is widespread in the mouse, BAT in humans mostly disappears between infancy and adulthood [34], although functional BAT is present in the region between the anterior neck and thorax [30]. The importance of these findings lies in the recently developed field of adipose tissue ‘beiging’. It is possible to stimulate white adipocytes to differentiate into a new adipocyte phenotype; the beige adipocyte, which bears resemblance to brown adipocytes in its number of mitochondria, and therefore, its ability to participate in thermogenesis [35, 36]. This process can be stimulated by increases in healthy sympathetic stimulation, i.e. exercise, as well as cold exposure and caloric restriction [35, 37, 38, 39]. The physiological importance of sympathetic nerve-induced beiging will be discussed below.

The composition of PVAT varies with its anatomical location [10, 11, 40, 41, 42, 43. Mesenteric and aortic PVAT is the most widely studied. Mesenteric PVAT primarily consists of WAT, although its adipocytes are relatively smaller than other visceral adipose depots [44, 45]. Expression of lipolytic genes in mesenteric PVAT is high; therefore, the rate of both basal and catecholamine-induced lipolysis is high in this vascular bed [44, 46]. In addition, expression of vascular endothelial growth factor is high, which is vital for expansion of adipose tissues in obesity [47]. Around the thoracic aorta, PVAT consists of BAT, whereas the abdominal aortic PVAT is a mixture [26, 43, 48]. Interestingly, this change in composition is thought to be linked to the development of atherosclerosis; the abdominal aorta is most susceptible to atherosclerosis, and expression of inflammatory markers in abdominal aortic mixed PVAT is high [48]. As discussed above, the BAT in thoracic aortic PVAT could have a protective effect. There have been some studies on PVAT surrounding coronary arteries. These studies indicate that, like mesenteric PVAT, coronary PVAT consists of small white adipocytes [49]. However, the secretory profile of coronary adipocytes is different. Expression of the vasodilator adipokine, adiponectin is low, and expression of pro-inflammatory factors is high [50]. This has been linked to development of hypertension and myocardial infarction [51, 52, 53].

Sympathetic Innervation of Adipose Tissue

The sympathetic nervous system (SNS) modulates lipolysis of WAT. Sympathetic denervation will impair lipolysis, and increase WAT expansion [54, 55, 56, 57]. Conversely, SNS activation will increase lipolysis [58]. In addition, this increase in lipolysis can be reduced by β-adrenoceptor inhibition. These studies clearly indicate that adipocytes express adrenoceptors which will respond to sympathetic nerve-derived catecholamines.

Electrophysiology studies confirm that sympathetic nerves are present in both WAT and BAT [59, 60], although the degree of activity in response to certain stimuli does vary between the two types [61]. In particular, SNS activity in WAT is increased by glucoprivation, cold exposure and food deprivation, increasing lipolysis and release of free fatty acids (FFAs). Whereas in BAT, only cold exposure will increase nerve activity, resulting in increased thermogenesis. Studies using retrograde viral tract tracers have indicated that nerve fibres present in adipose tissue originate from the general sympathetic nerve outflow of the central nervous system [55, 62, 63]. These studies also indicated the presence of sensory nerve fibres. The function of these sensory nerve fibres and their interaction with sympathetic nerves is unclear. It is likely that the sensory nerves sense products of lipolysis, feeding back onto the SNS in order to regulate lipolysis [62, 64]. However, a recent study has indicated that sensory nerves may directly stimulate the release of leptin from PVAT, which has a vasorelaxant effect on the vasculature [65].

The tight packing of adipocytes has made it difficult to visualise direct contact between nerves and adipocytes, and histological studies are conflicting. Studies using markers for sympathetic nerves agree that they are present in both BAT and WAT depots, including visceral, subcutaneous and perivascular depots [19, 66, 67, 68]. Whilst most tissues receive dual autonomic innervation, i.e. sympathetic and parasympathetic, 97–98% of nerves in adipose tissue are sympathetic [69]. Interestingly, a marker for vascular specific sympathetic nerves, neuropeptide tyrosine, is negative in BAT, indicating that adipocytes are innervated by a separate nerve population to the vasculature [67]. Whilst some studies have indicated a high degree of direct contact between nerves and adipocytes [66, 70, 71], others have determined that only 2–3% of adipocytes are directly innervated [68]. Therefore, it remains to be confirmed if adipocytes are directly innervated, or are responding to catecholamine spill over.

We have recently confirmed that the anti-contractile effect of PVAT in vitro is dependent upon sympathetic nerves [19]. Electrical stimulation (activating sympathetic nerves) of small mesenteric resistance arteries with and without PVAT demonstrates that PVAT exerts an anti-contractile effect, which can be abolished using pharmacological sympathetic denervation of the adipose tissue. Similar effects have been reported in the superior mesenteric artery, whereas in the aorta electrical stimulation induces a pro-contractile effect [15]. The difference between the two vascular beds can be explained by the adipose tissue phenotype: mesenteric PVAT comprises WAT, whereas aortic PVAT is BAT. Interestingly, the anti-contractile effect of PVAT in the mesenteric bed is absent in the spontaneously hypertensive rat, indicating the importance of PVAT function in blood pressure regulation [15]. In addition, when a greater electrical stimulus is used, mesenteric PVAT will exert a pro-contractile effect on the vasculature [72], suggesting that increased nerve activity will alter PVAT function.

PVAT Contains an Adrenergic System

As discussed previously, catecholamines induce lipolysis in WAT via adrenoceptors on adipocytes, in particular β3-adrenoceptors [71, 73]. In BAT, β3-adrenoceptors stimulate thermogenesis [74]. Previously, these metabolic functions were thought to be the only roles for adrenoceptors on adipocytes [75]; however, we now know that adipocyte β3-adrenoceptors regulate vascular tone. In larger conductive vessels, β3-adrenoceptors are present in the endothelium, and when stimulated will mediate vasorelaxation [76, 77, 78]. However, they are not present in the small resistance arteries which modulate blood pressure. Despite this, a specific β3-adrenoceptor agonist induces hypotension in canines and rodents [79]. Briones et al. [80] demonstrated that this same agonist will induce vasodilation in small arteries, only when PVAT is left intact. Similarly, the agonist induces PVAT-dependent hyperpolarisation of vascular smooth muscle cells [81]. Recently, using β3-adrenoceptor antagonists, we have confirmed that β3-adrenoceptors are vital in the PVAT anti-contractile effect, and that stimulation of β3-adrenoceptors triggers secretion of the vasodilator adiponectin from PVAT [19].

It is worth noting that all adrenoceptor subtypes are present on adipocytes, and they all play a role in modulating lipolysis (reviewed by Lafontan and Berlan [82]). Whilst β-adrenoceptors are stimulatory, α-adrenoceptors inhibit lipolysis. However, it appears that only adipocyte β3-adrenoceptor contribute to the PVAT anti-contractile effect.

The existence of a catecholamine system within adipocytes was first demonstrated by Pizzinat et al. [83]). This group reported the expression of monoamine oxidase A and B in adipocytes, indicating that adipocytes will uptake and metabolise monoamines such as noradrenaline (NA). Mesenteric WAT adipocytes [19, 84] and BAT [85] express organic cation transporter 3 (OCT3). OCT3 is a member of solute carrier family SLC2AA, and plays a vital role in extraneuronal transport of neurotransmitters such as NA into the periphery [86, 87, 88]. We have recently shown that OCT3 plays a functional role in PVAT anti-contractile effect, by enabling adipocytes to sequester sympathetic nerve-derived NA.

In addition to metabolising NA, it is possible that adipocytes are a source of NA [89]. When denervated aortic BAT and mesenteric WAT is stimulated with tyramine, the adipose tissue releases functional NA [89]. However, as discussed below, PVAT contains a diverse immune cell population, many of which can produce NA [90, 91]. Therefore, further investigation is required to determine if it is the adipocytes themselves producing NA.

Autonomic Imbalance in Obesity

It is widely accepted that the SNS is pathologically overactive in obesity [92, 93]. Overactivity has been confirmed in multiple skeletal muscle studies [94, 95, 96], as well as studies of the cardiac and renal nerves [97]. Most importantly, the degree of SNS overactivity positively correlates with body fat mass, and varies with the location of increased adiposity. In particular, SNS activity is highest in patients with excessive visceral adipose tissue [98]. The causative mechanisms of SNS overactivity are not well understood (reviewed by Lemche et al. [99] and Smith and Minson [92]); however, it is likely due to an imbalance in the hypothalamic-pituitary axis [100]. Changes in adipokine secretion will contribute to this imbalance. Leptin in particular is greatly increased in obesity, and has a stimulatory effect on the SNS; therefore, it is highly likely that leptin may be one driver of SNS overactivity in obesity.

One consequence of SNS overactivity in obesity is impaired catecholamine-induced lipolysis, which will contribute to adipocyte hyperplasia and hypertrophy [101, 102, 103, 104]. Basal lipolysis however, is increased [105]. This may be due to increases in expression of inflammatory cytokines, discussed further below, which exert a stimulatory effect on lipolysis [106, 107]. This increase in basal lipolysis will result in an increase in circulating FFAs, which will contribute to development of insulin resistance, glucose intolerance and hypertension through effects on skeletal muscle and the renin-angiotensin-aldosterone system [108, 109, 110, 111]. Studies in first-degree relatives of obese patients indicate that catecholamine-induced lipolysis is impaired in the offspring of obese patients [112]. This may suggest that impaired lipolysis occurs before expansion of adipose tissues. Indeed some studies have indicated that SNS overactivity occurs alarmingly early in response to a high-fat diet, before significant weight gain. In rats, only 12 days of a cafeteria diet induces SNS overactivity [113]. Similar rapid changes in SNS activity have been reported in humans with small changes in body weight, and the magnitude of SNS overactivity increases with the amount of weight gained [114].

With regard to PVAT function, it is possible that SNS overactivity will contribute to PVAT dysfunction in obesity. In heart failure patients, SNS overactivity results in desensitisation and internalisation of β-adrenoceptors [115]. It is possible that a similar effect occurs in adipose tissue, and SNS overactivity may result in β3-adrenoceptor internalisation in adipocytes, leading to reduced adiponectin release, and a loss of PVAT anti-contractile function. However, this has not yet been explored. For a summary of the potential effects of SNS overactivity in obesity, see Fig. 1.
Fig. 1

Consequences of SNS overactivity in PVAT. A high-fat diet will increase adipose tissue mass. In addition, in response to a high-fat diet, sympathetic nervous system (SNS) activity increased. One consequence of SNS overactivity is impaired catecholamine-induced lipolysis, which will contribute to increased adipose mass. It is possible that SNS overactivity may cause desensitisation and internalisation of adipocyte adrenoceptors. As a result of SNS overactivity, adipose tissue becomes inflamed and its secretory profile is altered. In particular, leptin secretion is increased, which will contribute to autonomic imbalance. Secretion of the vasodilator adiponectin is reduced, which will have direct effects on the vasculature, and may increase arterial tone. Infiltration of pro-inflammatory M1 macrophages is increased, which will increase expression of inflammatory cytokines including tumour necrosis factor α (TNF-α) and interleukin-6 (IL-6). Expression of anti-inflammatory cytokines is reduced. Changes to the immune cell populations will contribute to vascular dysfunction

Obesity-Induced Inflammation of PVAT

Numerous models of obesity, including genetic [116, 117] and diet-induced [11, 118], demonstrate a loss of the PVAT anti-contractile effect, which likely contributes to development of hypertension. However, not all obese patients develop hypertension, and not all hypertensive patients are obese. A key common feature between obese hypertensives and lean hypertensives is the inflammatory populations in adipose tissue [119, 120]. PVAT contains a rich population of innate and adaptive immune cells [121], which is rapidly altered in obesity. In obesity, the increased need for energy storage results in adipocyte hypertrophy [11]. In addition, catecholamine-induced lipolysis is impaired [101]; this may be contributory to changes in catecholamine sensitivity which has been independently related to systolic blood pressure changes in a study of healthy, normotensive patients, and therefore, may have profound effects in hypertension [122]. Hypertrophy is not accompanied by increases in vascularisation, leading to hypoxia and subsequent oxidative stress and chronic inflammation [123, 124]. When subjected to hypoxia in vitro, the loss of PVAT function in obesity can be replicated in small resistance arteries from mice and rats [11, 18], indicating the importance of hypoxia-induced changes to the PVAT environment. Moreover, this loss of function can be reversed in vitro using antioxidants and cytokine antagonists [11, 18, 125]. One characteristic of hypoxia in obesity is an increase in expression of pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) [126, 127]. Application of antibodies for these cytokines can reverse PVAT dysfunction in hypoxia [11]. The role of TNF-α in hypertension is uncertain; some studies have shown that elevated TNF-α levels have been associated with the development of hypertension [128] whereas others using the DOCA-salt model of hypertension have shown no link [129]. This may indicate a differing role in different causes of hypertension. Further to this, there is strong evidence to support a role for IL-6 in hypertension both from experimental models [130] and human data [131].

Macrophages represent a large proportion of the immune cell population in PVAT, and in obesity macrophages are the main source of TNF-α and IL-6 [132]. Interestingly, loss of PVAT function in hypoxia can be prevented in the absence of macrophages [18], indicating the importance of macrophages in the inflammatory process of PVAT. In lean adipose tissue, the macrophage phenotype is predominantly M2 macrophages (alternatively activated macrophages) which release anti-inflammatory cytokines such as interleukin-10 [133], and are a source of catecholamines [90]. However, in obesity, there is a phenotypic switch from M2 macrophages to M1 macrophages (classically activated macrophages) [134]. In addition, macrophage infiltration is increased in both human and mouse obesity [18, 135]. Further to this, a ‘macrophage-centric model’ has been proposed to support the interrelatedness of neural, renal and vascular contributions to hypertension (reviewed by Harwani et al. [136],). These studies suggest that it is increased M1 macrophage activation and infiltration in obesity which contribute significantly to the increases in pro-inflammatory cytokine expression in obesity. It is worth noting that adipocyte-derived M1 macrophages may contribute directly to vascular dysfunction in obesity by reducing bioavailability of the vasodilator hydrogen sulphide in the endothelium [137], which has been known to develop prior to blood pressure changes in the spontaneously hypertensive rat [138].

Eosinophils are present in large numbers in healthy PVAT; however, levels are decreased in obesity [91]. Interestingly, the PVAT anti-contractile effect is lost in eosinophil-deficient mice, which is accompanied by increased blood pressure and reduced glucose tolerance. We have demonstrated previously that this phenotype and PVAT function can be rescued by eosinophil transplant [91], highlighting the importance of eosinophils in regulating PVAT function. Similar to M2 macrophages, eosinophils are a source of catecholamines, and are able to stimulate production of adiponectin and nitric oxide (NO) via activation of adipocyte β3-adrenoceptors [91]. Studies are emerging that parasitic induced eosinophilia may confer metabolic benefits in obesity. This hypothesis stems from the low incidence of cardiovascular disease in developing countries where helminth infections are prevalent [139, 140]. In mice, eosinophilia induced by a helminth infection demonstrates an increase in M2 macrophage activation, and has shown promise in improving glucose tolerance in obesity [141]. These effects may be mediated via interleukin-4 secretion from eosinophils, which has been shown to increase M2 polarisation [142]. IL-4 levels have been seen to be lower in hypertensive patients compared with control [143], and serum IL-4 and gene expression levels are reduced in patients with a particular cholesteryl ester transfer protein Taq1B polymorphism, and is associated with hypertension in this group [144]. However, the direct link between hypertension and eosinophils remains to be fully understood at this stage.

There are a number of other immune cells in PVAT which may contribute to pathogenesis in obesity, although their roles in adipose tissue are not well studied. Neutrophils are present at low levels in healthy PVAT, and their number is increased in obesity [145], and decreased following bariatric surgery [146]. Interestingly, neutrophil numbers correlate with blood pressure variability in lean hypertensive patients [147], indicating a role for neutrophils in vascular dysfunction. It is likely that their role in producing a variety of reactive oxygen species (ROS) is contributory to this observation [148]. Mast cells follow a similar pattern of expression in adipose tissue to neutrophils, and mast cell gene deficiency protects against diet-induced weight gain, and enhances glucose tolerance [149]. Mast cells are host to a panel of vasoconstrictor agents which are likely to underpin their contribution to vascular dysfunction. T and B cells are also increased in adipose tissue in obesity [150, 151], and both may be implicated in obesity pathogenesis. In a pharmacological model of hypertension in lean mice, T cell numbers are increased [152]. Data from lymphocyte-deficient scid mice implicated an eNOS- and COX-2-dependent pathway [153]. In diet-induced obese mice, treatment with B cell-depleting antibodies protects against insulin resistance and glucose intolerance [151]. All of these studies represent the importance of adipose tissue immune cell research in understanding vascular dysfunction in obesity.

It is important to note that expression of adiponectin, one of the potential adipokines responsible for the anti-contractile effect in health, has been shown to be reduced in hypoxia [154]. This decrease in adiponectin would likely worsen the inflammatory response, as adiponectin inhibits inflammatory cytokine production [155]. Additionally, adiponectin receptor 2 plays an important role in revascularisation following ischaemic injury [156]. Therefore, it is possible that reduced circulating adiponectin in obesity may prevent vascularisation of increased adipose depots, leading to hypoxia and inflammation.

The Role of Sympathetic Nerves in Inflammation

The autonomic nervous system is integral to the inflammatory reflex [157]. The parasympathetic nerve-mediated cholinergic anti-inflammatory effect is well studied [158], whereas in comparison little attention is paid to the role of sympathetic nerves. Similar to parasympathetic nerves, sympathetic nerves have an important immunosuppressive role to play [159]. Whereas parasympathetic nerves regulate the number and function of lymphocytes, sympathetic nerves are involved in the control of granulocytes, including eosinophils, through adrenoceptors expressed on the surface of these cells [160]. Adrenoceptors are present on a number of immune cells, including splenocytes [161, 162, 163], macrophages [162, 164], T and B cells [165] and, as already mentioned, eosinophils [91]. Therefore, all of these immune cells will respond to sympathetic nerve-derived NA. Using retrograde tract tracers, sympathetic inputs to key components of the immune system including the thymus, bone marrow and lymph nodes have been well characterised [41, 166, 167]. Sympathetic input to lymph nodes is of particular significance in the context of this review, as PVAT is in close proximity to lymphatic organs, which likely enables the immune population in PVAT to alter rapidly in response to need [168]. In response to lipopolysaccharides, circulating TNF-α is increased, and this increase is greatly enhanced following sympathetic denervation of the spleen [163, 169]. Similarly, global sympathetic inhibition using reserpine elicited a similar enhancement of TNF-α production in response to lipopolysaccharides, and in this study, administration of β-adrenoceptor agonists reduced this enhancement of TNF-α production [162]. Macrophages are a large source of TNF-α, and express adrenoceptors; therefore, the effects of sympathetic denervation and reserpine on TNF-α may be mediated via increased macrophage activity. These studies indicate a clear role for sympathetic nerves in inflammation; therefore, it is likely that autonomic dysfunction in obesity may contribute to adipose inflammation (Fig. 1).

Effects of Exercise on Autonomic Function and Inflammation

Exercise, which is considered to be a healthy, physiological form of sympathetic nerve activation, is well known to have beneficial effects in a number of diseases, including hypertension, diabetes and tachycardia [170, 171], and there is evidence that these beneficial outcomes may be mediated via effects on adrenoceptor activity, and on immune cells. In addition, exercise has been shown to reduce pathological sympathetic nerve activity occurring in obesity [172].

During exercise, the nutrient and oxygen demands of skeletal muscle is increased; therefore, there is a need for an acute increase in vasodilation to increase blood flow to the muscle via resistance arteries [173]. During this time, the contractility of vascular smooth muscle cells is altered [174, 175]. It is thought that this change in blood flow is controlled locally by chemical mediators produced by the muscle, red blood cells and endothelial cells [173, 176, 177]. However, the acute exercise-induced vasodilation is very rapid, and has been observed within 1 s of commencing exercise [178]. Therefore, it is likely that there is an initial contribution from the mechanical effect of muscle squeezing the vessels and pushing blood into the muscle [176, 179, 180]. This will be maintained after approximately 5 s by vasoactive chemicals. In addition, vascular tone is regulated by the autonomic nervous system, and during exercise, sympathetic nerve-mediated vasoconstriction is increased. This action of the nerves will limit vasodilation, preventing overloading of the heart with blood [181]. Interplay during exercise between sympathetic nerve evoked vasoconstriction, and chemically induced local vasodilation results in only moderate changes in blood pressure [173].

Chronic exercise is known to improve cardiovascular function; including increasing blood flow capacity [173], although, the molecular pathways and their links to the beneficial effects of exercise in disease are still being explored. It is likely that chronic exercise results in changes in gene expression and causes adaptations which will increase the efficiency of the vasculature in responding to the needs of muscle during exercise [182]. Chronic exercise training has been shown to increase flow-mediated dilation in large muscle arteries, and endothelium-dependent dilation in resistance arteries [183, 184]. Multiple studies have suggested that the increase in shear stress and stretching of arterial walls triggers altered gene expression in endothelial cells (reviewed by Whyte and Laughlin [173]). Indeed, some research groups have suggested that this is what should be considered the ‘normal’ phenotype in endothelial cells, and endothelial cells in sedentary individuals are a deviation from the norm [173, 177, 185]. Healthy endothelial function is vital in a number of processes, such as smooth muscle cell proliferation and migration, innate immunity and maintaining an anti-inflammatory environment (reviewed by Mensah [186]). Therefore, improvements in endothelial function using exercise could be useful in obesity.

There is a multitude of evidence that exercise alters adrenoceptor expression and sensitivity in cardiac tissue. In mice, exercise training protects against myocardial reperfusion injury via upregulation of β3-adrenoceptors [187]. Similarly, intense exercise in diabetic rats demonstrated increased β3-adrenoceptor expression in the heart [188], although a similar study using the same diabetes model, with a less extensive training protocol, indicated improvements in β1-adrenoceptor expression, and no effect on β2/3-adrenoceptor expression [189]. Likewise, dogs with ventricular fibrillation exhibited increased β1-adrenoceptor in cardiac tissue following exercise training [190]. The effect of exercise on adrenoceptor expression extends to immune cells. In healthy humans, immediately after one exercise session, β-adrenoceptor expression was increased in lymphocytes, although there were no studies to specify which isoform [191]. Most importantly, for the context of this review, in the Otsuka Long-Evans Tokushima Fatty rat, voluntary exercise on provided exercise wheels increased β3-adrenoceptor gene expression in adipose tissue [192].

Whilst the effects of exercise on adrenoceptor expression in the vasculature are not well studied, there is at least some evidence that exercise improves responsiveness of diseased arteries. In atherosclerotic pigs, exercise improved the response of coronary arteries to endothelin-1 [193]. In the obese Zucker rat, exercise improved the vasodilator response of skeletal muscle arteries to arachidonic acid, as well as improving glucose tolerance [194]. In human obese patients, exercise improved flow-mediated dilation in both the brachial artery and forearm microvasculature [195, 196].

Some studies have shown that exercise alters adipokine secretion in obesity. Adiponectin is increased following exercise [197], and leptin is decreased [197, 198]. In addition, TNF-α expression is reduced in the adipose tissue of exercised diet-induced obese mice [199]. A number of studies have reported similar effects of exercise on inflammatory cells in skeletal muscle. In diet-induced obesity models, forced exercise reduced TNF-α and T cell expression, macrophage infiltration and induced a phenotypic switch of M1 macrophages to M2 [200, 201, 202]. These findings were independent of weight loss. Similarly, in a voluntary exercise study, TNF-α expression was reduced, and this was accompanied by improvements in insulin sensitivity and glucose tolerance [199]. Interestingly, an acute exercise study involving only one swimming session reduced TNF-α in adipose tissue, increased M2 macrophage polarisation and improved glucose signalling [203].

Of course we cannot exclude the role of weight loss in the beneficial effects of exercise. Lipolysis of WAT is regulated by SNS, and as a result of increased energy expenditure during exercise, lipolysis is increased [204], which will reduce fat mass and therefore, body weight. Exercise does reduce adipocyte size, and will increase mitochondrial bioavailability [205, 206, 207], which fits with the increase in energy expenditure required by exercise. In addition, sympathetic activation by exercise is associated with reduced food intake [98].

The Potential for Exercise-Induced Beiging of Adipose Tissue

As discussed previously, it is possible to stimulate white adipocytes to differentiate into beige adipocytes, which may confer the metabolic benefits of BAT. In a recent human trial, male obese patients were subjected to increasing periods of mild cold exposure (which is known to induce beiging [38, 39]) whilst their dietary intake was controlled [208]. Following only 10 days, patients exhibited significant improvements in glucose uptake, although there were no further studies to determine if this effect was sustained. The results of this study, and others like it, have made beiging adipocytes an attractive therapeutic target.

The activity of BAT is regulated by SNS [209], and as already discussed, exercise increases SNS activity. Therefore, it is likely that exercise will increase BAT activity. Many exercise studies, including running and swimming, have demonstrated that exercise stimulates beiging of WAT, and this is true for both forced and voluntary exercise [205, 210, 211]. Interestingly, the degree of beiging, quantified by measuring expression of uncoupling protein-1, does depend on the duration and type of exercise (reviewed by Dewal and Stanford [212]). Beiging appears to be much greater following periods of swimming than running, and most surprisingly, shorter durations of exercise (less than 3 weeks) are the most effective. It has been suggested that exercise-induced lipolysis, leading to a reduction in adipose mass [213], may become significant during longer training programmes.

Stanford et al. [211] have conducted a particularly illuminating study into the benefits of exercised-induced beiging. In this study, exercise wheels were provided to mice for voluntary exercise for 11 days. Using gene set analysis, Stanford et al. found that exercise increased expression of genes important to glucose metabolism as well as beiging. More excitingly, this group transplanted subcutaneous WAT from exercised trained mice into the visceral cavity of sedentary high-fat diet fed mice. Whilst the fat transplant had no effect on body weight, food intake or activity, 9 days post-transplant blood glucose, insulin and cholesterol were significantly improved in the high-fat diet mice. These effects were reduced 14 days post-surgery, and completely dissipated by 28 days. Nonetheless, these surprising results clearly demonstrate a beneficial effect of acutely exercised fat.

A number of mechanisms behind exercise-induced beiging and the beneficial metabolic effects have been proposed which involve increased SNS activity. The simplest theory is that exercise increases BAT activity, which results in increased energy expenditure and therefore, weight loss [214]. Another suggestion is that exercise, or other factors which induce beiging, may disrupt fur growth, resulting in a need to increase thermogenesis and therefore, BAT. However, as discussed above, exercise appears to affect adrenoceptor expression and activity, and some studies have demonstrated that β3-adrenoceptor agonists induce beiging [215, 216, 217]. Similarly, the herbal supplement curcumin has been shown to stimulate beiging via increasing β3-adrenoceptor expression in WAT [218], and cold-induced beiging is dependent upon β3-adrenoceptors [219]. Therefore, it is likely that the exercised-induced beiging mechanism involves β3-adrenoceptors. As previously discussed, the PVAT anti-contractile effect is dependent upon β3-adrenoceptors; therefore, it is possible that exercise may be useful in restoring PVAT function in obesity via effects on β3-adrenoceptor expression and activity. For a summary of the potential effects of SNS activation using exercise in obesity, see Fig. 2.
Fig. 2

The potential benefits of exercise on obese PVAT. Exercise is considered healthy sympathetic nervous system (SNS) activity, and has been shown to have multiple benefits in obesity. Lipolysis is increased, contributing to weight loss, and exercise has been shown to improve adrenoceptor expression in cardiac tissue. In adipose tissue, the adipokine secretion profile is improved which will have direct effects on the vasculature. In addition, exercise reduces inflammation; tumour necrosis factor α (TNF-α) and interleukin-6 (IL-6) expression is reduced, and macrophages undergo a phenotypic switch to anti-inflammatory M2 macrophages. Exercise has been shown to induce beiging of white adipose tissue, quantified by expression of uncoupling protein-1 (UCP-1). This process will enable thermogenesis, which result in an improved metabolic profile via increased energy expenditure

Summary

In addition to modulating metabolism, sympathetic nerves in PVAT modulate the release of vasoactive factors from adipocytes, which exert an anti-contractile effect on the vasculature; reducing peripheral resistance and therefore, blood pressure. Autonomic dysfunction in response to a high-fat diet contributes to adipose tissue expansion and recruitment of inflammatory cells in PVAT. Hypoxia and chronic inflammation result in PVAT dysfunction, and the overactivity of sympathetic nerves may be causing internalisation of adipocyte adrenoceptors. Healthy sympathetic hyperstimulation by exercise reduces expression of inflammatory cells in PVAT, and may improve expression of adrenoceptors; therefore, exercise may be useful in restoring PVAT function in obesity. In addition, exercise may be inducing transformation of white adipocytes to beige adipocytes, which confer an improved metabolic phenotype. Clearly, the study of sympathetic innervation of adipose tissue is vital to gain new insights into vascular dysfunction in obesity.

Notes

Author Contributions

All authors contributed to (I) conception and design, (II) administrative support, (III) provision of study materials or patients, (IV) collection and assembly of data, (V) data analysis and interpretation, (VI) manuscript writing and (VII) final approval of manuscript.

Funding

This work was supported by the British Heart Foundation (PG/16/52/32229).

Compliance with Ethical Standards

Conflicts of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    National Health Service (2018). Statistics on obesity, physical activity and diet. https://files.digital.nhs.uk/publication/0/0/obes-phys-acti-diet-eng-2018-rep.pdf. Accessed 17-10-18
  2. 2.
    Oda E: Definition of metabolic syndrome. In Stroke United States, 2007, p. e152.Google Scholar
  3. 3.
    Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–9.CrossRefPubMedGoogle Scholar
  4. 4.
    National Health Service (2016). Statistics on obesity physical activity and diet. http://content.digital.nhs.uk/catalogue/PUB20562/obes-phys-acti-diet-eng-2016-rep.pdf. Accessed 17-10-18.
  5. 5.
    Purcell K, Sumithran P, Prendergast LA, Bouniu CJ, Delbridge E, Proietto J. The effect of rate of weight loss on long-term weight management: a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2:954–62.CrossRefPubMedGoogle Scholar
  6. 6.
    Aghamohammadzadeh R, Heagerty AM. Obesity-related hypertension: epidemiology, pathophysiology, treatments, and the contribution of perivascular adipose tissue. Ann Med. 2012;44(Suppl 1):S74–84.CrossRefPubMedGoogle Scholar
  7. 7.
    Bjorndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J Obes. 2011;2011:490650.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic smooth muscle responsiveness. Clin Exp Hypertens A. 1991;13:277–96.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–56.CrossRefPubMedGoogle Scholar
  10. 10.
    Szasz T, Webb RC. Perivascular adipose tissue: more than just structural support. Clin Sci (Lond). 2012;122:1–12.CrossRefGoogle Scholar
  11. 11.
    Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska M, et al. Local inflammation and hypoxia abolish the protective anticontractile properties of perivascular fat in obese patients. Circulation. 2009;119:1661–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Boydens C, Maenhaut N, Pauwels B, Decaluwe K, Van de Voorde J. Adipose tissue as regulator of vascular tone. Curr Hypertens Rep. 2012;14:270–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Maenhaut N, Van de Voorde J. Regulation of vascular tone by adipocytes. BMC Med. 2011;9:25.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Yiannikouris F, Gupte M, Putnam K, Cassis L. Adipokines and blood pressure control. Curr Opin Nephrol Hypertens. 2010;19:195–200.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Torok J, Zemancikova A, Kocianova Z. Interaction of perivascular adipose tissue and sympathetic nerves in arteries from normotensive and hypertensive rats. Physiol Res. 2016;65:S391–s399.PubMedGoogle Scholar
  16. 16.
    de Boer MP, Meijer RI, Richter EA, van Nieuw Amerongen GP, Sipkema P, van Poelgeest EM, et al. Globular adiponectin controls insulin-mediated vasoreactivity in muscle through AMPKalpha2. Vasc Pharmacol. 2016;78:24–35.CrossRefGoogle Scholar
  17. 17.
    Galvez-Prieto B, Somoza B, Gil-Ortega M, Garcia-Prieto CF, de Las Heras AI, Gonzalez MC, et al. Anticontractile effect of perivascular adipose tissue and leptin are reduced in hypertension. Front Pharmacol. 2012;3:103.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Withers SB, Agabiti-Rosei C, Livingstone DM, Little MC, Aslam R, Malik RA, et al. Macrophage activation is responsible for loss of anticontractile function in inflamed perivascular fat. Arterioscler Thromb Vasc Biol. 2011;31:908–13.CrossRefPubMedGoogle Scholar
  19. 19.
    Saxton SN, Ryding KE, Aldous RG, Withers SB, Ohanian J, Heagerty AM. Role of sympathetic nerves and adipocyte catecholamine uptake in the vasorelaxant function of perivascular adipose tissue. Arterioscler Thromb Vasc Biol. 2018;38:880–91.CrossRefPubMedGoogle Scholar
  20. 20.
    Rittig K, Staib K, Machann J, Bottcher M, Peter A, Schick F, et al. Perivascular fatty tissue at the brachial artery is linked to insulin resistance but not to local endothelial dysfunction. Diabetologia. 2008;51:2093–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Reifenberger MS, Turk JR, Newcomer SC, Booth FW, Laughlin MH. Perivascular fat alters reactivity of coronary artery: effects of diet and exercise. Med Sci Sports Exerc. 2007;39:2125–34.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Yudkin JS, Eringa E, Stehouwer CD. “Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet. 2005;365:1817–20.CrossRefPubMedGoogle Scholar
  23. 23.
    Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9:191–200.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cinti S. Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. J Endocrinol Investig. 2002;25:823–35.CrossRefGoogle Scholar
  25. 25.
    Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin N Am. 2008;37:753–68 x-xi.CrossRefGoogle Scholar
  26. 26.
    Galvez-Prieto B, Dubrovska G, Cano MV, Delgado M, Aranguez I, Gonzalez MC, et al. A reduction in the amount and anti-contractile effect of periadventitial mesenteric adipose tissue precedes hypertension development in spontaneously hypertensive rats. Hypertens Res. 2008;31:1415–23.CrossRefPubMedGoogle Scholar
  27. 27.
    Takaoka M, Nagata D, Kihara S, Shimomura I, Kimura Y, Tabata Y, et al. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res. 2009;105:906–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Kiefer FW, Cohen P, Plutzky J. Fifty shades of brown: perivascular fat, thermogenesis, and atherosclerosis. In: Circulation United States. 2012. p. 1012–1015.Google Scholar
  29. 29.
    Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: a mini-review. Gerontology. 2012;58:15–23.CrossRefPubMedGoogle Scholar
  30. 30.
    Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, et al. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509–17.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. N Engl J Med. 2007;356:213–5.CrossRefGoogle Scholar
  32. 32.
    Stanford KI, Middelbeek RJ, Townsend KL, An D, Nygaard EB, Hitchcox KM, et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest. 2013;123:215–23.CrossRefPubMedGoogle Scholar
  33. 33.
    Liu X, Wang S, You Y, Meng M, Zheng Z, Dong M, et al. Brown adipose tissue transplantation reverses obesity in Ob/Ob mice. Endocrinology. 2015;156:2461–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Yoneshiro T, Aita S, Matsushita M, Okamatsu-Ogura Y, Kameya T, Kawai Y, et al. Age-related decrease in cold-activated brown adipose tissue and accumulation of body fat in healthy humans. Obesity (Silver Spring). 2011;19:1755–60.CrossRefGoogle Scholar
  35. 35.
    Himms-Hagen J, Melnyk A, Zingaretti MC, Ceresi E, Barbatelli G, Cinti S. Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes. Am J Physiol Cell Physiol. 2000;279:C670–81.CrossRefGoogle Scholar
  36. 36.
    Warner A, Kjellstedt A, Carreras A, Bottcher G, Peng XR, Seale P, et al. Activation of beta3-adrenoceptors increases in vivo free fatty acid uptake and utilization in brown but not white fat depots in high-fat-fed rats. Am J Physiol Endocrinol Metab. 2016;311:E901–e910.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Fabbiano S, Suarez-Zamorano N, Rigo D, Veyrat-Durebex C, Stevanovic Dokic A, Colin DJ, et al. Caloric restriction leads to browning of white adipose tissue through type 2 immune signaling. Cell Metab. 2016;24:434–46.CrossRefPubMedGoogle Scholar
  38. 38.
    Cousin B, Cinti S, Morroni M, Raimbault S, Ricquier D, Penicaud L, et al. Occurrence of brown adipocytes in rat white adipose tissue: molecular and morphological characterization. J Cell Sci. 1992;103(Pt 4):931–42.PubMedGoogle Scholar
  39. 39.
    Guerra C, Koza RA, Yamashita H, Walsh K, Kozak LP. Emergence of brown adipocytes in white fat in mice is under genetic control. Effects on body weight and adiposity. J Clin Invest. 1998;102:412–20.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Aghamohammadzadeh R, Withers S, Lynch F, Greenstein A, Malik R, Heagerty A. Perivascular adipose tissue from human systemic and coronary vessels: the emergence of a new pharmacotherapeutic target. Br J Pharmacol. 2012;165:670–82.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Bulloch K, Moore RY. Innervation of the thymus gland by brain stem and spinal cord in mouse and rat. Am J Anat. 1981;162:157–66.CrossRefPubMedGoogle Scholar
  42. 42.
    Galvez-Prieto B, Bolbrinker J, Stucchi P, de Las Heras AI, Merino B, Arribas S, et al. Comparative expression analysis of the renin-angiotensin system components between white and brown perivascular adipose tissue. J Endocrinol. 2008;197:55–64.CrossRefPubMedGoogle Scholar
  43. 43.
    Bulloch JM, Daly CJ. Autonomic nerves and perivascular fat: interactive mechanisms. Pharmacol Ther. 2014;143:61–73.CrossRefPubMedGoogle Scholar
  44. 44.
    Palou M, Priego T, Sanchez J, Rodriguez AM, Palou A, Pico C. Gene expression patterns in visceral and subcutaneous adipose depots in rats are linked to their morphologic features. Cell Physiol Biochem. 2009;24:547–56.CrossRefPubMedGoogle Scholar
  45. 45.
    Wronska A, Kmiec Z. Structural and biochemical characteristics of various white adipose tissue depots. Acta Physiol (Oxf). 2012;205:194–208.CrossRefGoogle Scholar
  46. 46.
    Ahmadian M, Wang Y, Sul HS. Lipolysis in adipocytes. Int J Biochem Cell Biol. 2010;42:555–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Ye J. Adipose tissue vascularization: its role in chronic inflammation. Curr Diab Rep. 2011;11:203–10.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Padilla J, Jenkins NT, Vieira-Potter VJ, Laughlin MH. Divergent phenotype of rat thoracic and abdominal perivascular adipose tissues. Am J Physiol Regul Integr Comp Physiol. 2013;304:R543–52.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Chatterjee TK, Stoll LL, Denning GM, Harrelson A, Blomkalns AL, Idelman G, et al. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res. 2009;104:541–9.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006;5:1.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006;47:1108–16.CrossRefPubMedGoogle Scholar
  52. 52.
    Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. Jama. 2004;291:1730–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Teijeira-Fernandez E, Eiras S, Grigorian-Shamagian L, Fernandez A, Adrio B, Gonzalez-Juanatey JR. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. J Hum Hypertens. 2008;22:856–63.CrossRefPubMedGoogle Scholar
  54. 54.
    Lazzarini SJ, Wade GN. Role of sympathetic nerves in effects of estradiol on rat white adipose tissue. Am J Phys. 1991;260:R47–51.Google Scholar
  55. 55.
    Bamshad M, Aoki VT, Adkison MG, Warren WS, Bartness TJ. Central nervous system origins of the sympathetic nervous system outflow to white adipose tissue. Am J Phys. 1998;275:R291–9.Google Scholar
  56. 56.
    Rooks CR, Penn DM, Kelso E, Bowers RR, Bartness TJ, Harris RB. Sympathetic denervation does not prevent a reduction in fat pad size of rats or mice treated with peripherally administered leptin. Am J Physiol Regul Integr Comp Physiol. 2005;289:R92–102.CrossRefPubMedGoogle Scholar
  57. 57.
    Foster MT, Bartness TJ. Sympathetic but not sensory denervation stimulates white adipocyte proliferation. Am J Physiol Regul Integr Comp Physiol. 2006;291:R1630–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Correll JW. Adipose tissue: ability to respond to nerve stimulation in vitro. Science. 1963;140:387–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Egawa M, Yoshimatsu H, Bray GA. Effects of 2-deoxy-D-glucose on sympathetic nerve activity to interscapular brown adipose tissue. Am J Phys. 1989;257:R1377–85.Google Scholar
  60. 60.
    Niijima A. Nervous regulation of metabolism. Prog Neurobiol. 1989;33:135–47.CrossRefPubMedGoogle Scholar
  61. 61.
    Brito NA, Brito MN, Bartness TJ. Differential sympathetic drive to adipose tissues after food deprivation, cold exposure or glucoprivation. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1445–52.CrossRefPubMedGoogle Scholar
  62. 62.
    Song CK, Schwartz GJ, Bartness TJ. Anterograde transneuronal viral tract tracing reveals central sensory circuits from white adipose tissue. Am J Physiol Regul Integr Comp Physiol. 2009;296:R501–11.CrossRefPubMedGoogle Scholar
  63. 63.
    Nguyen NL, Randall J, Banfield BW, Bartness TJ. Central sympathetic innervations to visceral and subcutaneous white adipose tissue. Am J Physiol Regul Integr Comp Physiol. 2014;306:R375–86.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Bartness TJ, Shrestha YB, Vaughan CH, Schwartz GJ, Song CK. Sensory and sympathetic nervous system control of white adipose tissue lipolysis. Mol Cell Endocrinol. 2010;318:34–43.CrossRefPubMedGoogle Scholar
  65. 65.
    Abu Bakar H, Dunn WR, Daly C, Ralevic V. Sensory innervation of perivascular adipose tissue: a crucial role in artery vasodilatation and leptin release. Cardiovasc Res. 2017.Google Scholar
  66. 66.
    Wirsen C. Adrenergic innervation of adipose tissue examined by fluorescence microscopy. Nature. 1964;202:913.CrossRefPubMedGoogle Scholar
  67. 67.
    Cannon B, Nedergaard J, Lundberg JM, Hokfelt T, Terenius L, Goldstein M. ‘Neuropeptide tyrosine’ (NPY) is co-stored with noradrenaline in vascular but not in parenchymal sympathetic nerves of brown adipose tissue. Exp Cell Res. 1986;164:546–50.CrossRefPubMedGoogle Scholar
  68. 68.
    Slavin BG, Ballard KW. Morphological studies on the adrenergic innervation of white adipose tissue. Anat Rec. 1978;191:377–89.CrossRefPubMedGoogle Scholar
  69. 69.
    Giordano A, Song CK, Bowers RR, Ehlen JC, Frontini A, Cinti S, Bartness TJ. White adipose tissue lacks significant vagal innervation and immunohistochemical evidence of parasympathetic innervation. In: Am J Physiol Regul Integr Comp Physiol United States. 2006. p. R1243–R1255.Google Scholar
  70. 70.
    Lever JD, Jung RT, Nnodim JO, Leslie PJ, Symons D. Demonstration of a catecholaminergic innervation in human perirenal brown adipose tissue at various ages in the adult. Anat Rec. 1986;215:251–5 227-259.CrossRefPubMedGoogle Scholar
  71. 71.
    Rebuffe-Scrive M. Neuroregulation of adipose tissue: molecular and hormonal mechanisms. Int J Obes. 1991;15(Suppl 2):83–6.PubMedGoogle Scholar
  72. 72.
    Gao YJ, Takemori K, Su LY, An WS, Lu C, Sharma AM, et al. Perivascular adipose tissue promotes vasoconstriction: the role of superoxide anion. Cardiovasc Res. 2006;71:363–73.CrossRefPubMedGoogle Scholar
  73. 73.
    Robidoux J, Kumar N, Daniel KW, Moukdar F, Cyr M, Medvedev AV, et al. Maximal beta3-adrenergic regulation of lipolysis involves Src and epidermal growth factor receptor-dependent ERK1/2 activation. J Biol Chem. 2006;281:37794–802.CrossRefPubMedGoogle Scholar
  74. 74.
    Cypess AM, Weiner LS, Roberts-Toler C, Franquet Elia E, Kessler SH, Kahn PA, et al. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab. 2015;21:33–8.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Dessy C, Balligand JL. Beta3-adrenergic receptors in cardiac and vascular tissues emerging concepts and therapeutic perspectives. Adv Pharmacol. 2010;59:135–63.CrossRefPubMedGoogle Scholar
  76. 76.
    Oriowo MA. Atypical beta-adrenoceptors in the rat isolated common carotid artery. Br J Pharmacol. 1994;113:699–702.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    MacDonald A, McLean M, MacAulay L, Shaw AM. Effects of propranolol and L-NAME on beta-adrenoceptor-mediated relaxation in rat carotid artery. J Auton Pharmacol. 1999;19:145–9.CrossRefPubMedGoogle Scholar
  78. 78.
    Trochu JN, Leblais V, Rautureau Y, Beverelli F, Le Marec H, Berdeaux A, et al. Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol. 1999;128:69–76.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Shen YT, Cervoni P, Claus T, Vatner SF. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J Pharmacol Exp Ther. 1996;278:1435–43.PubMedGoogle Scholar
  80. 80.
    Briones AM, Daly CJ, Jimenez-Altayo F, Martinez-Revelles S, Gonzalez JM, McGrath JC, et al. Direct demonstration of beta1- and evidence against beta2- and beta3-adrenoceptors, in smooth muscle cells of rat small mesenteric arteries. Br J Pharmacol. 2005;146:679–91.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Weston AH, Egner I, Dong Y, Porter EL, Heagerty AM, Edwards G. Stimulated release of a hyperpolarizing factor (ADHF) from mesenteric artery perivascular adipose tissue: involvement of myocyte BKCa channels and adiponectin. Br J Pharmacol. 2013;169:1500–9.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res. 1993;34:1057–91.PubMedGoogle Scholar
  83. 83.
    Pizzinat N, Marti L, Remaury A, Leger F, Langin D, Lafontan M, et al. High expression of monoamine oxidases in human white adipose tissue: evidence for their involvement in noradrenaline clearance. Biochem Pharmacol. 1999;58:1735–42.CrossRefPubMedGoogle Scholar
  84. 84.
    Ayala-Lopez N, Jackson WF, Burnett R, Wilson JN, Thompson JM, Watts SW. Organic cation transporter 3 contributes to norepinephrine uptake into perivascular adipose tissue. Am J Physiol Heart Circ Physiol. 2015;309:H1904–14.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Breining P, Pedersen SB, Pikelis A, Rolighed L, Sundelin EIO, Jessen N, et al. High expression of organic cation transporter 3 in human BAT-like adipocytes. Implications for extraneuronal norepinephrine uptake. Mol Cell Endocrinol. 2017;443:15–22.CrossRefPubMedGoogle Scholar
  86. 86.
    Grundemann D, Schechinger B, Rappold GA, Schomig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998;1:349–51.CrossRefPubMedGoogle Scholar
  87. 87.
    Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004;308:2–9.CrossRefPubMedGoogle Scholar
  88. 88.
    Ingoglia F, Visigalli R, Rotoli BM, Barilli A, Riccardi B, Puccini P, et al. Functional characterization of the organic cation transporters (OCTs) in human airway pulmonary epithelial cells. Biochim Biophys Acta. 1848;2015:1563–72.Google Scholar
  89. 89.
    Ayala-Lopez N, Martini M, Jackson WF, Darios E, Burnett R, Seitz B, et al. Perivascular adipose tissue contains functional catecholamines. Pharmacol Res Perspect. 2014;2:e00041.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011;480:104–8.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Withers SB, Forman R, Meza-Perez S, Sorobetea D, Sitnik K, Hopwood T, et al. Eosinophils are key regulators of perivascular adipose tissue and vascular functionality. Sci Rep. 2017;7:44571.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Smith MM, Minson CT. Obesity and adipokines: effects on sympathetic overactivity. J Physiol. 2012;590:1787–801.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol. 2014;12:4–15.CrossRefPubMedGoogle Scholar
  94. 94.
    Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560–3.CrossRefPubMedGoogle Scholar
  95. 95.
    Jones PP, Davy KP, Seals DR. Relations of total and abdominal adiposity to muscle sympathetic nerve activity in healthy older males. Int J Obes Relat Metab Disord. 1997;21:1053–7.CrossRefPubMedGoogle Scholar
  96. 96.
    Scherrer U, Randin D, Tappy L, Vollenweider P, Jequier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89:2634–40.CrossRefPubMedGoogle Scholar
  97. 97.
    Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125–33.CrossRefPubMedGoogle Scholar
  98. 98.
    Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann N Y Acad Sci. 2006;1083:129–52.CrossRefPubMedGoogle Scholar
  99. 99.
    Lemche E, Chaban OS, Lemche AV. Neuroendorine and epigentic mechanisms subserving autonomic imbalance and HPA dysfunction in the metabolic syndrome. Front Neurosci. 2016;10:142.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Chrousos GP. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord. 2000;24(Suppl 2):S50–5.CrossRefPubMedGoogle Scholar
  101. 101.
    Large V, Reynisdottir S, Langin D, Fredby K, Klannemark M, Holm C, et al. Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. J Lipid Res. 1999;40:2059–66.PubMedGoogle Scholar
  102. 102.
    Langin D, Dicker A, Tavernier G, Hoffstedt J, Mairal A, Ryden M, et al. Adipocyte lipases and defect of lipolysis in human obesity. Diabetes. 2005;54:3190–7.CrossRefPubMedGoogle Scholar
  103. 103.
    Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, Nio-Kobayashi J, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes. 2009;58:1526–31.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Vijgen GH, Bouvy ND, Teule GJ, Brans B, Hoeks J, Schrauwen P, et al. Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2012;97:E1229–33.CrossRefPubMedGoogle Scholar
  105. 105.
    Reynisdottir S, Langin D, Carlstrom K, Holm C, Rossner S, Arner P. Effects of weight reduction on the regulation of lipolysis in adipocytes of women with upper-body obesity. Clin Sci (Lond). 1995;89:421–9.CrossRefGoogle Scholar
  106. 106.
    Langin D, Arner P. Importance of TNFalpha and neutral lipases in human adipose tissue lipolysis. Trends Endocrinol Metab. 2006;17:314–20.CrossRefPubMedGoogle Scholar
  107. 107.
    Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK. Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab. 2004;89:5577–82.CrossRefPubMedGoogle Scholar
  108. 108.
    Safonova I, Aubert J, Negrel R, Ailhaud G. Regulation by fatty acids of angiotensinogen gene expression in preadipose cells. Biochem J. 1997;322(Pt 1):235–9.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Aubert J, Safonova I, Negrel R, Ailhaud G. Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells. Biochem Biophys Res Commun. 1998;250:77–82.CrossRefPubMedGoogle Scholar
  110. 110.
    Lafontan M, Langin D. Lipolysis and lipid mobilization in human adipose tissue. Prog Lipid Res. 2009;48:275–97.CrossRefPubMedGoogle Scholar
  111. 111.
    Kolditz CI, Langin D. Adipose tissue lipolysis. Curr Opin Clin Nutr Metab Care. 2010;13:377–81.CrossRefPubMedGoogle Scholar
  112. 112.
    Hellstrom L, Langin D, Reynisdottir S, Dauzats M, Arner P. Adipocyte lipolysis in normal weight subjects with obesity among first-degree relatives. Diabetologia. 1996;39:921–8.CrossRefPubMedGoogle Scholar
  113. 113.
    Muntzel MS, Al-Naimi OA, Barclay A, Ajasin D. Cafeteria diet increases fat mass and chronically elevates lumbar sympathetic nerve activity in rats. In: Hypertension United States. 2012. p. 1498–1502.Google Scholar
  114. 114.
    Davy KP, Orr JS. Sympathetic nervous system behavior in human obesity. Neurosci Biobehav Rev. 2009;33:116–24.CrossRefPubMedGoogle Scholar
  115. 115.
    Post SR, Hammond HK, Insel PA. Beta-adrenergic receptors and receptor signaling in heart failure. Annu Rev Pharmacol Toxicol. 1999;39:343–60.CrossRefPubMedGoogle Scholar
  116. 116.
    Fesus G, Dubrovska G, Gorzelniak K, Kluge R, Huang Y, Luft FC, et al. Adiponectin is a novel humoral vasodilator. Cardiovasc Res. 2007;75:719–27.CrossRefPubMedGoogle Scholar
  117. 117.
    Marchesi C, Ebrahimian T, Angulo O, Paradis P, Schiffrin EL. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension. 2009;54:1384–92.CrossRefPubMedGoogle Scholar
  118. 118.
    Ma L, Ma S, He H, Yang D, Chen X, Luo Z, et al. Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats. Hypertens Res. 2010;33:446–53.CrossRefPubMedGoogle Scholar
  119. 119.
    Nosalski R, Guzik TJ. Perivascular adipose tissue inflammation in vascular disease. Br J Pharmacol. 2017;174:3496–513.CrossRefPubMedPubMedCentralGoogle Scholar
  120. 120.
    Madec S, Chiarugi M, Santini E, Rossi C, Miccoli P, Ferrannini E, et al. Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens. 2010;28:1459–65.CrossRefPubMedGoogle Scholar
  121. 121.
    McLaughlin T, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest. 2017;127:5–13.CrossRefPubMedPubMedCentralGoogle Scholar
  122. 122.
    Hoffstedt J, Reynisdottir S, Lonnqvist F. Systolic blood pressure is related to catecholamine sensitivity in subcutaneous abdominal fat cells. Obes Res. 1996;4:21–6.CrossRefPubMedGoogle Scholar
  123. 123.
    Kabon B, Nagele A, Reddy D, Eagon C, Fleshman JW, Sessler DI, et al. Obesity decreases perioperative tissue oxygenation. Anesthesiology. 2004;100:274–80.CrossRefPubMedPubMedCentralGoogle Scholar
  124. 124.
    de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem. 2008;54:945–55.CrossRefPubMedGoogle Scholar
  125. 125.
    Aghamohammadzadeh R, Unwin RD, Greenstein AS, Heagerty AM. Effects of obesity on perivascular adipose tissue vasorelaxant function: nitric oxide, inflammation and elevated systemic blood pressure. J Vasc Res. 2015;52:299–305.CrossRefPubMedGoogle Scholar
  126. 126.
    Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007;56:901–11.CrossRefPubMedGoogle Scholar
  127. 127.
    Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br J Nutr. 2008;100:227–35.CrossRefPubMedGoogle Scholar
  128. 128.
    Ito H, Ohshima A, Tsuzuki M, Ohto N, Takao K, Hijii C, et al. Association of serum tumour necrosis factor-alpha with serum low-density lipoprotein-cholesterol and blood pressure in apparently healthy Japanese women. Clin Exp Pharmacol Physiol. 2001;28:188–92.CrossRefPubMedGoogle Scholar
  129. 129.
    Elmarakby AA, Quigley JE, Imig JD, Pollock JS, Pollock DM. TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2008;294:R76–83.CrossRefPubMedGoogle Scholar
  130. 130.
    Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006;290:H935–40.CrossRefPubMedGoogle Scholar
  131. 131.
    Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149–54.CrossRefPubMedGoogle Scholar
  132. 132.
    Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808.CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35.CrossRefPubMedGoogle Scholar
  134. 134.
    Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84.CrossRefPubMedPubMedCentralGoogle Scholar
  135. 135.
    Aghamohammadzadeh R, Greenstein AS, Yadav R, Jeziorska M, Hama S, Soltani F, et al. Effects of bariatric surgery on human small artery function: evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile activity despite persistent obesity. J Am Coll Cardiol. 2013;62:128–35.CrossRefPubMedPubMedCentralGoogle Scholar
  136. 136.
    Harwani SC. Macrophages under pressure: the role of macrophage polarization in hypertension. Transl Res. 2018;191:45–63.CrossRefPubMedGoogle Scholar
  137. 137.
    Candela J, Wang R, White C. Microvascular endothelial dysfunction in obesity is driven by macrophage-dependent hydrogen sulfide depletion. Arterioscler Thromb Vasc Biol. 2017;37:889–99.CrossRefPubMedGoogle Scholar
  138. 138.
    Yan H, Du J, Tang C. The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biophys Res Commun. 2004;313:22–7.CrossRefPubMedGoogle Scholar
  139. 139.
    Blackwell AD, Trumble BC, Maldonado Suarez I, Stieglitz J, Beheim B, Snodgrass JJ, et al. Immune function in Amazonian horticulturalists. Ann Hum Biol. 2016;43:382–96.CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    Kaplan H, Thompson RC, Trumble BC, Wann LS, Allam AH, Beheim B, et al. Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. Lancet. 2017;389:1730–9.CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Wu D, Molofsky AB, Liang HE, Ricardo-Gonzalez RR, Jouihan HA, Bando JK, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332:243–7.CrossRefPubMedPubMedCentralGoogle Scholar
  142. 142.
    Makita N, Hizukuri Y, Yamashiro K, Murakawa M, Hayashi Y. IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration. Int Immunol. 2015;27:131–41.CrossRefPubMedGoogle Scholar
  143. 143.
    Ji Q, Cheng G, Ma N, Huang Y, Lin Y, Zhou Q, et al. Circulating Th1, Th2, and Th17 levels in hypertensive patients. Dis Markers. 2017;2017:7146290.CrossRefPubMedPubMedCentralGoogle Scholar
  144. 144.
    Ahmed AI, Helal MM, Kassem KF. Cholesteryl ester transfer protein Taq1B (g.5454G>A) gene polymorphism in primary combined hyperlipidemia in the Egyptian population. Lab Med. 2011;42:482–6.CrossRefGoogle Scholar
  145. 145.
    Ferrante AW Jr. The immune cells in adipose tissue. Diabetes Obes Metab. 2013;15(Suppl 3):34–8.CrossRefPubMedPubMedCentralGoogle Scholar
  146. 146.
    Berisha SZ, Serre D, Schauer P, Kashyap SR, Smith JD. Changes in whole blood gene expression in obese subjects with type 2 diabetes following bariatric surgery: a pilot study. PLoS One. 2011;6:e16729.CrossRefPubMedPubMedCentralGoogle Scholar
  147. 147.
    Kilicaslan B, Dursun H, Kaymak S, Aydin M, Ekmekci C, Susam I, et al. The relationship between neutrophil to lymphocyte ratio and blood pressure variability in hypertensive and normotensive subjects. Turk Kardiyol Dern Ars. 2015;43:18–24.CrossRefPubMedGoogle Scholar
  148. 148.
    Rudolph V, Rudolph TK, Freeman BA. Blood pressure regulation: role for neutrophils? Blood. 2008;111:4840.CrossRefPubMedGoogle Scholar
  149. 149.
    Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med. 2009;15:940–5.CrossRefPubMedPubMedCentralGoogle Scholar
  150. 150.
    Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation. 2007;115:1029–38.CrossRefPubMedGoogle Scholar
  151. 151.
    Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med. 2011;17:610–7.CrossRefPubMedPubMedCentralGoogle Scholar
  152. 152.
    Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–60.CrossRefPubMedPubMedCentralGoogle Scholar
  153. 153.
    Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1089–97.CrossRefPubMedPubMedCentralGoogle Scholar
  154. 154.
    Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun. 2006;341:549–56.CrossRefPubMedGoogle Scholar
  155. 155.
    Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96:1723–32.Google Scholar
  156. 156.
    Parker-Duffen JL, Nakamura K, Silver M, Zuriaga MA, MacLauchlan S, Aprahamian TR, et al. Divergent roles for adiponectin receptor 1 (AdipoR1) and AdipoR2 in mediating revascularization and metabolic dysfunction in vivo. J Biol Chem. 2014;289:16200–13.CrossRefPubMedPubMedCentralGoogle Scholar
  157. 157.
    Tracey KJ. The inflammatory reflex. Nature. 2002;420:853–9.CrossRefPubMedGoogle Scholar
  158. 158.
    Pereira MR, Leite PE. The involvement of parasympathetic and sympathetic nerve in the inflammatory reflex. J Cell Physiol. 2016;231:1862–9.CrossRefPubMedGoogle Scholar
  159. 159.
    Hori T, Katafuchi T, Take S, Shimizu N, Niijima A. The autonomic nervous system as a communication channel between the brain and the immune system. Neuroimmunomodulation. 1995;2:203–15.CrossRefPubMedGoogle Scholar
  160. 160.
    Abo T, Kawamura T. Immunomodulation by the autonomic nervous system: therapeutic approach for cancer, collagen diseases, and inflammatory bowel diseases. Ther Apher. 2002;6:348–57.CrossRefPubMedGoogle Scholar
  161. 161.
    Katafuchi T, Take S, Hori T. Roles of sympathetic nervous system in the suppression of cytotoxicity of splenic natural killer cells in the rat. J Physiol. 1993;465:343–57.CrossRefPubMedPubMedCentralGoogle Scholar
  162. 162.
    Szelenyi J, Kiss JP, Vizi ES. Differential involvement of sympathetic nervous system and immune system in the modulation of TNF-alpha production by alpha2- and beta-adrenoceptors in mice. J Neuroimmunol. 2000;103:34–40.CrossRefPubMedGoogle Scholar
  163. 163.
    Kees MG, Pongratz G, Kees F, Scholmerich J, Straub RH. Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharide-induced TNF secretion in perfused rat spleen. J Neuroimmunol. 2003;145:77–85.CrossRefPubMedGoogle Scholar
  164. 164.
    Ignatowski TA, Gallant S, Spengler RN. Temporal regulation by adrenergic receptor stimulation of macrophage (M phi)-derived tumor necrosis factor (TNF) production post-LPS challenge. J Neuroimmunol. 1996;65:107–17.CrossRefPubMedGoogle Scholar
  165. 165.
    Nance DM, Sanders VM. Autonomic innervation and regulation of the immune system (1987-2007). Brain Behav Immun. 2007;21:736–45.CrossRefPubMedPubMedCentralGoogle Scholar
  166. 166.
    Romeo HE, Fink T, Yanaihara N, Weihe E. Distribution and relative proportions of neuropeptide Y- and proenkephalin-containing noradrenergic neurones in rat superior cervical ganglion: separate projections to submaxillary lymph nodes. Peptides. 1994;15:1479–87.CrossRefPubMedGoogle Scholar
  167. 167.
    Denes A, Boldogkoi Z, Uhereczky G, Hornyak A, Rusvai M, Palkovits M, et al. Central autonomic control of the bone marrow: multisynaptic tract tracing by recombinant pseudorabies virus. Neuroscience. 2005;134:947–63.CrossRefPubMedGoogle Scholar
  168. 168.
    Iikuni N, Lam QL, Lu L, Matarese G, La Cava A. Leptin and inflammation. Curr Immunol Rev. 2008;4:70–9.CrossRefPubMedPubMedCentralGoogle Scholar
  169. 169.
    Martelli D, Yao ST, McKinley MJ, McAllen RM. Reflex control of inflammation by sympathetic nerves, not the vagus. J Physiol. 2014;592:1677–86.CrossRefPubMedPubMedCentralGoogle Scholar
  170. 170.
    Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007;116:2110–8.CrossRefPubMedPubMedCentralGoogle Scholar
  171. 171.
    Hautala AJ, Kiviniemi AM, Tulppo MP. Individual responses to aerobic exercise: the role of the autonomic nervous system. Neurosci Biobehav Rev. 2009;33:107–15.CrossRefPubMedGoogle Scholar
  172. 172.
    de Jonge L, Moreira EA, Martin CK, Ravussin E. Impact of 6-month caloric restriction on autonomic nervous system activity in healthy, overweight, individuals. Obesity (Silver Spring). 2010;18:414–6.CrossRefGoogle Scholar
  173. 173.
    Whyte JJ, Laughlin MH. The effects of acute and chronic exercise on the vasculature. Acta Physiol (Oxf). 2010;199:441–50.CrossRefGoogle Scholar
  174. 174.
    Delp MD, Laughlin MH. Regulation of skeletal muscle perfusion during exercise. Acta Physiol Scand. 1998;162:411–9.CrossRefPubMedGoogle Scholar
  175. 175.
    Thomas GD, Segal SS. Neural control of muscle blood flow during exercise. J Appl Physiol (1985). 2004;97:731–8.CrossRefGoogle Scholar
  176. 176.
    Clifford PS. Skeletal muscle vasodilatation at the onset of exercise. J Physiol. 2007;583:825–33.CrossRefPubMedPubMedCentralGoogle Scholar
  177. 177.
    Laughlin MH, Roseguini B. Mechanisms for exercise training-induced increases in skeletal muscle blood flow capacity: differences with interval sprint training versus aerobic endurance training. J Physiol Pharmacol. 2008;59(Suppl 7):71–88.PubMedPubMedCentralGoogle Scholar
  178. 178.
    Kirby BS, Carlson RE, Markwald RR, Voyles WF, Dinenno FA. Mechanical influences on skeletal muscle vascular tone in humans: insight into contraction-induced rapid vasodilatation. J Physiol. 2007;583:861–74.CrossRefPubMedPubMedCentralGoogle Scholar
  179. 179.
    Laughlin MH. Skeletal muscle blood flow capacity: role of muscle pump in exercise hyperemia. Am J Phys. 1987;253:H993–1004.Google Scholar
  180. 180.
    Tschakovsky ME, Sheriff DD. Immediate exercise hyperemia: contributions of the muscle pump vs. rapid vasodilation. J Appl Physiol (1985). 2004;97:739–47.CrossRefGoogle Scholar
  181. 181.
    Raven PB. Recent advances in baroreflex control of blood pressure during exercise in humans: an overview. Med Sci Sports Exerc. 2008;40:2033–6.CrossRefPubMedGoogle Scholar
  182. 182.
    Hansen AK, Fischer CP, Plomgaard P, Andersen JL, Saltin B, Pedersen BK. Skeletal muscle adaptation: training twice every second day vs. training once daily. J Appl Physiol (1985). 2005;98:93–9.CrossRefGoogle Scholar
  183. 183.
    Jasperse JL, Laughlin MH. Endothelial function and exercise training: evidence from studies using animal models. Med Sci Sports Exerc. 2006;38:445–54.CrossRefPubMedPubMedCentralGoogle Scholar
  184. 184.
    Walther G, Nottin S, Karpoff L, Perez-Martin A, Dauzat M, Obert P. Flow-mediated dilation and exercise-induced hyperaemia in highly trained athletes: comparison of the upper and lower limb vasculature. Acta Physiol (Oxf). 2008;193:139–50.CrossRefGoogle Scholar
  185. 185.
    Booth FW, Roberts CK. Linking performance and chronic disease risk: indices of physical performance are surrogates for health. Br J Sports Med. 2008;42:950–2.CrossRefPubMedGoogle Scholar
  186. 186.
    Mensah GA. Healthy endothelium: the scientific basis for cardiovascular health promotion and chronic disease prevention. Vasc Pharmacol. 2007;46:310–4.CrossRefGoogle Scholar
  187. 187.
    Calvert JW, Condit ME, Aragon JP, Nicholson CK, Moody BF, Hood RL, et al. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of beta(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ Res. 2011;108:1448–58.CrossRefPubMedPubMedCentralGoogle Scholar
  188. 188.
    Lahaye Sle D, Gratas-Delamarche A, Malarde L, Vincent S, Zguira MS, Morel SL, et al. Intense exercise training induces adaptation in expression and responsiveness of cardiac beta-adrenoceptors in diabetic rats. Cardiovasc Diabetol. 2010;9:72.CrossRefPubMedGoogle Scholar
  189. 189.
    Bidasee KR, Zheng H, Shao CH, Parbhu SK, Rozanski GJ, Patel KP. Exercise training initiated after the onset of diabetes preserves myocardial function: effects on expression of beta-adrenoceptors. J Appl Physiol (1985). 2008;105:907–14.CrossRefGoogle Scholar
  190. 190.
    Holycross BJ, Kukielka M, Nishijima Y, Altschuld RA, Carnes CA, Billman GE. Exercise training normalizes beta-adrenoceptor expression in dogs susceptible to ventricular fibrillation. Am J Physiol Heart Circ Physiol. 2007;293:H2702–9.CrossRefPubMedGoogle Scholar
  191. 191.
    Fujii N, Shibata T, Homma S, Ikegami H, Murakami K, Miyazaki H. Exercise-induced changes in beta-adrenergic-receptor mRNA level measured by competitive RT-PCR. J Appl Physiol (1985). 1997;82:1926–31.CrossRefGoogle Scholar
  192. 192.
    Jenkins NT, Padilla J, Rector RS, Laughlin MH. Influence of regular physical activity and caloric restriction on beta-adrenergic and natriuretic peptide receptor expression in retroperitoneal adipose tissue of OLETF rats. Exp Physiol. 2013;98:1576–84.CrossRefPubMedGoogle Scholar
  193. 193.
    Bunker AK, Laughlin MH. Influence of exercise and perivascular adipose tissue on coronary artery vasomotor function in a familial hypercholesterolemic porcine atherosclerosis model. J Appl Physiol (1985). 2010;108:490–7.CrossRefGoogle Scholar
  194. 194.
    Sebai M, Lu S, Xiang L, Hester RL. Improved functional vasodilation in obese Zucker rats following exercise training. Am J Physiol Heart Circ Physiol. 2011;301:H1090–6.CrossRefPubMedPubMedCentralGoogle Scholar
  195. 195.
    Hallmark R, Patrie JT, Liu Z, Gaesser GA, Barrett EJ, Weltman A. The effect of exercise intensity on endothelial function in physically inactive lean and obese adults. PLoS One. 2014;9:e85450.CrossRefPubMedPubMedCentralGoogle Scholar
  196. 196.
    Franco RL, Fallow BA, Huang CJ, Acevedo EO, Arrowood JA, Evans RK. Forearm blood flow response to acute exercise in obese and non-obese males. Eur J Appl Physiol. 2013;113:2015–23.CrossRefPubMedGoogle Scholar
  197. 197.
    Golbidi S, Laher I. Exercise induced adipokine changes and the metabolic syndrome. J Diabetes Res. 2014;2014:726861.CrossRefPubMedPubMedCentralGoogle Scholar
  198. 198.
    Zachwieja JJ, Hendry SL, Smith SR, Harris RB. Voluntary wheel running decreases adipose tissue mass and expression of leptin mRNA in Osborne-Mendel rats. Diabetes. 1997;46:1159–66.CrossRefPubMedGoogle Scholar
  199. 199.
    Bradley RL, Jeon JY, Liu FF, Maratos-Flier E. Voluntary exercise improves insulin sensitivity and adipose tissue inflammation in diet-induced obese mice. Am J Physiol Endocrinol Metab. 2008;295:E586–94.CrossRefPubMedPubMedCentralGoogle Scholar
  200. 200.
    Kawanishi N, Yano H, Yokogawa Y, Suzuki K. Exercise training inhibits inflammation in adipose tissue via both suppression of macrophage infiltration and acceleration of phenotypic switching from M1 to M2 macrophages in high-fat-diet-induced obese mice. Exerc Immunol Rev. 2010;16:105–18.PubMedGoogle Scholar
  201. 201.
    Kawanishi N, Mizokami T, Yano H, Suzuki K. Exercise attenuates M1 macrophages and CD8+ T cells in the adipose tissue of obese mice. Med Sci Sports Exerc. 2013;45:1684–93.CrossRefPubMedGoogle Scholar
  202. 202.
    Samaan MC, Marcinko K, Sikkema S, Fullerton MD, Ziafazeli T, Khan MI, et al. Endurance interval training in obese mice reduces muscle inflammation and macrophage content independently of weight loss. Physiol Rep. 2014;2.Google Scholar
  203. 203.
    Oliveira AG, Araujo TG, Carvalho BM, Guadagnini D, Rocha GZ, Bagarolli RA, et al. Acute exercise induces a phenotypic switch in adipose tissue macrophage polarization in diet-induced obese rats. Obesity (Silver Spring). 2013;21:2545–56.CrossRefGoogle Scholar
  204. 204.
    Jordy AB, Kiens B. Regulation of exercise-induced lipid metabolism in skeletal muscle. Exp Physiol. 2014;99:1586–92.CrossRefPubMedGoogle Scholar
  205. 205.
    Stanford KI, Middelbeek RJ, Goodyear LJ. Exercise effects on white adipose tissue: beiging and metabolic adaptations. Diabetes. 2015;64:2361–8.CrossRefPubMedPubMedCentralGoogle Scholar
  206. 206.
    Trevellin E, Scorzeto M, Olivieri M, Granzotto M, Valerio A, Tedesco L, et al. Exercise training induces mitochondrial biogenesis and glucose uptake in subcutaneous adipose tissue through eNOS-dependent mechanisms. Diabetes. 2014;63:2800–11.CrossRefPubMedGoogle Scholar
  207. 207.
    Stallknecht B, Vinten J, Ploug T, Galbo H. Increased activities of mitochondrial enzymes in white adipose tissue in trained rats. Am J Phys. 1991;261:E410–4.Google Scholar
  208. 208.
    Hanssen MJ, van der Lans AA, Brans B, Hoeks J, Jardon KM, Schaart G, et al. Short-term cold acclimation recruits brown adipose tissue in obese humans. Diabetes. 2016;65:1179–89.CrossRefPubMedGoogle Scholar
  209. 209.
    van Marken Lichtenbelt W. Brown adipose tissue and the regulation of nonshivering thermogenesis. Curr Opin Clin Nutr Metab Care. 2012;15:547–52.CrossRefPubMedGoogle Scholar
  210. 210.
    Cao L, Choi EY, Liu X, Martin A, Wang C, Xu X, et al. White to brown fat phenotypic switch induced by genetic and environmental activation of a hypothalamic-adipocyte axis. Cell Metab. 2011;14:324–38.CrossRefPubMedPubMedCentralGoogle Scholar
  211. 211.
    Stanford KI, Middelbeek RJ, Townsend KL, Lee MY, Takahashi H, So K, et al. A novel role for subcutaneous adipose tissue in exercise-induced improvements in glucose homeostasis. Diabetes. 2015;64:2002–14.CrossRefPubMedPubMedCentralGoogle Scholar
  212. 212.
    Dewal RS, Stanford KI. Effects of exercise on brown and beige adipocytes. Biochim Biophys Acta Mol Cell Biol Lipids. 2018.Google Scholar
  213. 213.
    Ranallo RF, Rhodes EC. Lipid metabolism during exercise. Sports Med. 1998;26:29–42.CrossRefPubMedGoogle Scholar
  214. 214.
    Nedergaard J, Cannon B. The browning of white adipose tissue: some burning issues. Cell Metab. 2014;20:396–407.CrossRefPubMedGoogle Scholar
  215. 215.
    Lee YH, Petkova AP, Mottillo EP, Granneman JG. In vivo identification of bipotential adipocyte progenitors recruited by beta3-adrenoceptor activation and high-fat feeding. Cell Metab. 2012;15:480–91.CrossRefPubMedPubMedCentralGoogle Scholar
  216. 216.
    Park JW, Jung KH, Lee JH, Quach CH, Moon SH, Cho YS, et al. 18F-FDG PET/CT monitoring of beta3 agonist-stimulated brown adipocyte recruitment in white adipose tissue. J Nucl Med. 2015;56:153–8.CrossRefPubMedGoogle Scholar
  217. 217.
    Merlin J, Sato M, Chia LY, Fahey R, Pakzad M, Nowell CJ, et al. Rosiglitazone and a beta3-adrenoceptor agonist are both required for functional browning of white adipocytes in culture. Front Endocrinol (Lausanne). 2018;9:249.CrossRefGoogle Scholar
  218. 218.
    Wang S, Wang X, Ye Z, Xu C, Zhang M, Ruan B, et al. Curcumin promotes browning of white adipose tissue in a norepinephrine-dependent way. Biochem Biophys Res Commun. 2015;466:247–53.CrossRefPubMedGoogle Scholar
  219. 219.
    Jimenez M, Barbatelli G, Allevi R, Cinti S, Seydoux J, Giacobino JP, et al. Beta 3-adrenoceptor knockout in C57BL/6J mice depresses the occurrence of brown adipocytes in white fat. Eur J Biochem. 2003;270:699–705.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2019

OpenAccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Division of Cardiovascular Sciences, Manchester Academic Health Science CentreUniversity of ManchesterManchesterUK
  2. 2.School of Environment and Life SciencesUniversity of SalfordManchesterUK

Personalised recommendations